Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting

CONCLUSION: This study supports ixazomib-based therapy as an effective and tolerable treatment in the real-world. Outcomes were favorable in patients with 1 or ≥ 2 prior lines of therapy who were not lenalidomide- or PI-refractory.PMID:37996265 | DOI:10.1016/j.clml.2023.10.003

Source: Clinical Lymphoma and Myeloma - November 23, 2023 Category: Cancer & Oncology Authors: Heinz Ludwig Karthik Ramasamy Mar ía-Victoria Mateos Bhuvan Kishore Varga Gergely Miriam Ladicka Alessandra Ori Lucia Simoni Nawal Bent-Ennakhil Dawn Marie Stull Fran çois Gavini Evangelos Terpos Roman H ájek Source Type: research